Vascular endothelial growth factor and hepatic neoangiogenesis in hepatitis C associated chronic liver disease

Agamy, Maha Mohamed; Galal, Ghada Moustafa; Salah ElDeen, Eman Muhammad; Ahmad, Nagwa Sayed; Mohammad, Asmaa Naser; Mahmoud, Shereen

doi:10.21608/smj.2017.41281

Vascular endothelial growth factor and hepatic neoangiogenesis in hepatitis C associated chronic liver disease

Document Type : Original Article

Authors

¹ Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.

² Department of pathology, Faculty of Medicine, Sohag University.

³ Debartment of Biochemistry, Faculty of Medicine, Sohag University.

10.21608/smj.2017.41281

Abstract

Worldwide Egypt had the highest prevalence of hepatitis C virus infection. Angiogenesis is a complex process that regulated by many factors, including vascular endothelial growth factor (VEGF).in the liver HSCs, Kupffer cells, regenerating hepatocytes and existing endothelial cells are responsible for the process of neo angiogenesis and production of vascular endothelial growth factor (VEGF).
Aim of the work: To detect the significance vascular endothelial growth factor and its relation to hepatic neoangiogenesis in hepatitis C associated chronic liver disease. Methods: A total of 70 adult patients with chronic hepatitis C infection in various stages with no evidence of cirrhosis, were recruited for the study. We studied the expression of VEGF and vascular density in liver specimens from chronic HCV infected patients using a computer-based analysis of immunohistochemical staining and confirmed it by Western Blot.
Results: Relation between stage of fibrosis and laboratory finding was done there were significant relation between the stage of fibrosis and platelet count, also, the level of liver enzyme (AST and ALT) significantly related to the fibrosis stage, Serum albumin significantly related to fibrosis stage. The most important findings that VEGF level were significantly related to fibrosis stage.
Conclusion: Angiogenesis was present in 45.5% cases of chronic liver disease. It was proportional to the increase in stage of fibrosis. Expression of VEGF was commonly found in early stages of fibrosis.

References

Pybus O, Drummond A, Nakano T, et al. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. MolBiolEvol. 2003;20(3):381–387.

2- García-Monzón C, Sánchez-Madrid F, García-Buey L, García-Arroyo A, et al. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tract. Gastroenterology 1995; 08: 231-41.

3- Yamaguchi R, Yano H, Nakashima O, et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:152–160.

4- Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195.

5- Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42(Suppl): S22–36.

6- Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195.

7- Lai WK, Adams DH. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J Hepatol 2005; 45: 7-11.

8- Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, et al. Vascular adhesion molecule expression in viral chronic hepatitis:evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-241.

9- Hassan M, Selimovic D, Ghozlan H, et al.Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009;49(5):1469–82.

10- Abe M, Koga H, Yoshida T, et al. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factorkB/ hypoxia-inducible factor-1a axis under hypoxic conditions Hepatology Research 2012; 42(6): 591–600.

11- Liang Y, Shilagard T, Xiao SY, et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009;137(4):1448–58.

12- Mukozu T, Nagal H, Matsui D, et al. Serum VEGF as a Tumor Marker in Patients with HCV-related Liver Cirrhosis and Hepatocellular Carcinoma. ANTICANCER RESEARCH 2013 ; 33: 1013-22.

13- Helaly GF, AbouShamaLA . Influence of hepatitis C virus infection on circulating sI CAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancingdetection of HCC. The Egyptian journal of immunology 2006; 13 (1) :27-38.

14- Janczewska-Kazek E, Marek B, KajdaniukD ,Borgiel-Marek H. Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C.World J Gastroenterol. 2006;12(6) : 961-5.

15- Sieghart W, Fellner S, Reiberger T, et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Dig Liver Dis 2009; 41(12):902–6.

16- Brdoskey SV, Mendolov N, Melamed M, Ramaswamy G. Vascular density and VEGF expression in hepatic lesions. J Gaterointestin Liver Dis 2007;16 (4):343-77.

17- Mohsen M. Maher, MD, Tarek Yossef, MD, Shereen A. Saleh, MD NesrineA Mohamed, MD, RamyAwara. Journal of medical science and clinical research 2015 ;3 (4):5070-5082.

18- Koff R, Younossi Z, Reddy R ,Shiffman M. Debate: hepatitis C with normal liver enzymes: to treat or not to treat. Am J Gastroenterol 2004;99(6):972-6.

19- De Ritis F, Coltorti M, Giusti G. Anenzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. Clin. Chim. Acta 2006; 369 (2):148–52.

20- hiffman ML, Diago M, Tran A, et al.Chronic hepatitis C in patients withpersistently normal alanine transaminaselevels. Clin Gastroenterol Hepatol 2006;4(5):645-52.

21- Talaat RM. Soluble Angiogenesis Factors in Sera of Egyptian Patients with Hepatitis C Virus Infection: Correlation with Disease Severity.VIRAL IMMUNOLOGY 2010; 23 (2):151–7.

22- Assy N, Paizi M, Gaitini D et al. Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. World J Gastroenterol.1999 ;5(4):296-300.

23- Yao X, Miao W, Li M, et al. Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. Neurosci Lett 2010 ;472(3): 179-83.

24- Chongsrisawata V, Vejchapipatb P, Poovorawana Y. Serum vascular endothelial growth factor per platelet count in patients with biliary atresia. Asian Biomedicine 2010; 4 (2) :223-9.

25- Kim SJ, Choi IK, Park KH, et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. J ClinOncol 2004; 34 (4): 184- 90.

26- GunsilusE, Gastle G. Platelets and vascular endothelial growth factor blood level in cancer patients. British Journal of Cancer 1999; 81 (1): 184-6